What’s Next for Nektar Therapeutics?
On March 14 2022, The Nektar Therapeutics (NASDAQ: NKTR) announced that a review by an independent Data Monitoring Committee (DMC) evaluating the safety and efficacy of bempegaldesleukin in combination with Opdivo (nivolumab), revealed that the study has failed to meet the primary endpoints of progression-free...
